NCT05291091: An ongoing trial by Edgewise Therapeutics, Inc.
This trial is ongoing. It must report results 1 year, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05291091 |
|---|---|
| Title | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 10, 2022 |
| Completion date | Sept. 30, 2026 |
| Required reporting date | Sept. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |